Breast

Most recent

Twitter feed

Dr. Irwindeep Sandhu provides an analysis of the TOURMALINE-MM3 study with post-ASCT patients receiving #ixazomib m… https://t.co/ll9s4q7vCL
h J R
Dr. Brian Leber discusses long-term follow-up of patients with #myelofibrosis treated with #JAK inhibitors #EHA2019… https://t.co/G4FuspL3NK
h J R
Dr. Darrell White writes about the impact of age on efficacy and safety from the MAIA trial in transplant-ineligibl… https://t.co/00XDPvNCVo
h J R
Dr. Irwindeep Sandhu talks about the importance of studying real-world Canadian data in #multiplemyeloma #EHA2019… https://t.co/WHNsd75EPZ
h J R
Dr. Brian Leber discusses a re-analysis of the JAKARTA-2 study in patients with myeloproliferative neoplasm-associa… https://t.co/GyZFmwk7sq
h J R

Other

Single-Agent First-Line Therapy

NE Oncology Issue - June 2007 New data show improved clinical activity of nab-paclitaxel compared with docetaxel in patients with advanced breast cancer Background The first generation taxanes, paclitaxel and docetaxel, have provided major improvements in the...

Canadian perspective by Dr. Chia

NE Oncology Issue - June 2007 This was the second analysis presented for this large phase II trial. The data were interesting in that it appears we can deliver more nab-paclitaxel (450 mg/m2) with acceptable toxicity and improved progression-free survival compared to...

Canadian Perspective by Dr. Chia

NE Oncology Issue - June 2007 This is a relatively small phase III trial that mirrors a study that has already been published comparing nab-paclitaxel with paclitaxel.2 The results are comparable to the published study in terms of better response rates and time to...

Combination Therapy for First-Line Treatment of Metastatic Breast Cancer

NE Oncology Issue - June 2007 Lesley McKarney First-line data for lapatinib in HER2-positive advanced breast cancer is encouraging Background In tumours of 20% to 25% of women with breast cancer, the human epidermal growth factor receptor-2 (HER2) gene is amplified,...

Canadian perspective by Dr. Chia

NE Oncology Issue - June 2007 This trial was performed in patients with metastatic breast cancer who had no prior chemotherapy. Paclitaxel is commonly used in many parts of the world where there is no access to drugs like trastuzumab or the ability to test for HER2...

Adding a platinum to a taxane plus trastuzumab does not add to efficacy

NE Oncology Issue - June 2007 Background By binding to HER2 protein receptors, trastuzumab interrupts the growth signal, thereby slowing the growth and spread of breast cancer cells. In this way, trastuzumab, a monoclonal antibody, targets breast cancer cells that...

Canadian perspective by Dr. Chia

NE Oncology Issue - June 2007 In spite of its demonstrated activity in metastatic breast cancer, the application of platinum-based chemotherapy in clinical practice has been typically hampered by concerns about toxicity and the lack of proven survival effects.1 There...

Twitter feed

Dr. Irwindeep Sandhu provides an analysis of the TOURMALINE-MM3 study with post-ASCT patients receiving #ixazomib m… https://t.co/ll9s4q7vCL
h J R
Dr. Brian Leber discusses long-term follow-up of patients with #myelofibrosis treated with #JAK inhibitors #EHA2019… https://t.co/G4FuspL3NK
h J R
Dr. Darrell White writes about the impact of age on efficacy and safety from the MAIA trial in transplant-ineligibl… https://t.co/00XDPvNCVo
h J R
Dr. Irwindeep Sandhu talks about the importance of studying real-world Canadian data in #multiplemyeloma #EHA2019… https://t.co/WHNsd75EPZ
h J R
Dr. Brian Leber discusses a re-analysis of the JAKARTA-2 study in patients with myeloproliferative neoplasm-associa… https://t.co/GyZFmwk7sq
h J R